Dr Gideon Hirschfield from the University of Toronto Centre for Liver Disease discusses the potential of new drugs, including selective PPAR agents such as seladelpar, for the treatment of primary biliary cholangitis.
Dr Gideon Hirschfield from the University of Toronto Centre for Liver Disease discusses the potential of new drugs, including selective PPAR agents such as seladelpar, for the treatment of primary biliary cholangitis.
Dr Gideon Hirschfield from the...